CARNITOR SF
Details
- Status
- Prescription
- First Approved
- 1986-04-10
- Routes
- ORAL
- Dosage Forms
- SOLUTION
CARNITOR SF Approval History
What CARNITOR SF Treats
5 indicationsCARNITOR SF is approved for 5 conditions since its original approval in 1986. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Carnitine Deficiency
- Reye-like Encephalopathy
- Hypoglycemia
- Cardiomyopathy
- Inborn Error of Metabolism
Drugs Similar to CARNITOR SF
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CARNITOR SF FDA Label Details
ProIndications & Usage
FDA Label (PDF)CARNITOR ® (levocarnitine) is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularl...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.